Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft versus Host Disease

Alan Sugar,Munira Hussain,Winston Chamberlain,Reza Dana, D. Patrick Kelly,Christopher Ta,John Irvine, Melissa Daluvoy, Victor Perez, Joshua Olson,Vishal Jhanji,Terence A. Walts,R. Doyle Stulting,Edmund K. Waller,Neera Jagirdar,Alan Sugar,Shahzad Mian,Roni Shtein,H. Kaz Soong,Munira Hussain,Winston Chamberlain,Afshan Nanji,John Clements, Jennifer Maykovski, Paula Cisternas Labadzinzki,Reza Dana, Jia Jin,Joseph Ciolino, John Caccaviello, D. Patrick Kelly, Roya Habibi,Christopher Ta, Charles Yu,Charles Lin,Kristin Hirabayashi, Gabriel Valerio, Supriya Kawale, Mariana Nunez,John Irvine,Olivia Lee, Matthew Chu, Melissa Daluvoy, Victor Perez, Elmer Balajonda, Terry Hawks, Joshua Olson,Amanda Maltry,Joshua Hou, Wendy Elasky,Vishal Jhanji, Rose Carla Aubourg,R. Doyle Stulting,Edmund Waller,Neera Jagirdar,Terence Walts

Ophthalmology Science（2022）

引用 4|浏览7

暂无评分

摘要

Fibrinogen-depleted human platelet lysate appears to be well tolerated, with no significant toxicity at concentrations of 10% and 30%. These initial data suggest some efficacy, especially for subjective outcome measures relative to baseline assessments and treatment with the vehicle, but larger studies are needed to confirm these effects.

查看译文

关键词

Dry eye disease,Graft versus host disease,Human platelet,Ocular surface,Serum tears

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要